US FDA approval Orchid's ANDA for Cefpodoxime Proxetil
17 Nov 2007
The US FDA has approved the Chennai-based Orchid Chemicals & Pharmaceuticals Ltd abbreviated new drug application (ANDA) for Cefpodoxime Proxetil Tablets.
The product is available in two dosage strengths, 100 mg and 200 mg.
Cefpodoxime Proxetil is a 3rd generation cephalosporin antibiotic which has a broad spectrum activity against organisms causing infectious diseases.
With limited generic competition in this product, Orchid hopes to acquire a sizeable market share and revenues in the US market.